4.6 Review

CXCL16 in kidney and cardiovascular injury

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 25, Issue 3, Pages 317-325

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2014.04.002

Keywords

Atherosclerosis; Chemokine; Chronic kidney disease; Inflammation

Funding

  1. FIS [PS09/00447, PI13/00047]
  2. ISCIII-RETIC [REDinREN/RD06/0016, REDinREN/RD12/0021]
  3. Comunidad de Madrid [S2010/BMD-2378]
  4. Sociedad Espanola de Nefrologia
  5. ISCIII Sara Borrell
  6. ISCIII Rio Hortega
  7. Swedish Research Council

Ask authors/readers for more resources

CXC chemokine ligand 16 (CXCL16) is a CXC soluble chemokine, an adhesion molecule and a cell surface scavenger receptor. CXCL16 regulates inflammation, tissue injury and fibrosis. Parenchymal renal cells, vascular wall cells, leukocytes and platelets express and/or release CXCL16 under the regulation of inflammatory mediators. CXCL16 expression is increased in experimental and human nephropathies. Targeting CXCL16 protected from experimental glomerular injury or interstitial fibrosis. Conflicting results were reported for experimental cardiovascular injury. High circulating CXCL16 levels are associated to human kidney and cardiovascular disease and urinary CXCL16 may increase in kidney injury. In conclusion, mounting evidence suggests a role of CXCL16 in kidney and cardiovascular disease. However, a better understanding is still required before exploring CXCL16 targeting in the clinic. (C) 2014 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available